{
    "doi": "https://doi.org/10.1182/blood-2021-145421",
    "article_title": "Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma ",
    "article_date": "November 5, 2021",
    "session_type": "623.Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological",
    "abstract_text": "The R-BAC regimen is considered among standard first-line treatment for elderly fit patients with mantle cell lymphoma (MCL). In the previous R-BAC500 FIL trial, patients with the blastoid variant and/or high Ki67 proliferative index (High Risk - HR-) had a significantly higher risk of progression (2-years PFS of 40%), as compared to classical histologies and low proliferative index (Low Risk -LR-). When treated with R-BAC, LR patients had excellent outcome (median PFS not reached after 7 years), although no maintenance therapy was delivered. For this reason we designed a phase 2 trial that enrolled patients from 35 centers of the Fondazione Italiana Linfomi (FIL). At study entry, patients were centrally reviewed and stratified as \"low risk (LR)\", or \"high risk (HR)\", depending on morphology (blastoid versus others), Ki67 expression (\u226530% versus others), TP53 mutation/TP53 deletions (present versus not). Patients with any of the three risk factors were classified as HR. The primary endpoint was 2-years progression-free survival (PFS) for the HR patients. Patients had to be aged \u226565 years and fit according to the geriatric CGA assessment, or age \u226464 years if not eliglible to high-dose chemotherapy plus transplantation. Asymptomatic patients with non-nodal disease were excluded. Treatment consisted of 6 cycles of R-BAC (rituximab 375 mg/m2 d 1; bendamustine 70 mg/m2 d 1,2; cytarabine 500 mg/m2 d 1,2,3) for LR patients. HR patients received abbreviated induction with a maximum of 4 R-BAC followed by consolidation (4 months, 800 mg/d), and maintenance (20 months, 400 mg/d) with venetoclax. First patient was included on the 3rd of september, 2018, and last patient on the 20th of july, 2021. Overall, 140 patients were enrolled, of whom 52 were HR (37%). Median age was 72 (range 57-79), and 75% were males. The prevalence of TP53 mutations and deletions in the whole series was 21%, and 13%, respectively; Ki67 was \u226530% in 24%, and the blastoid variant was diagnosed in 9%. Demographic characteristics of HR versus LR patients (127 patients with available data at the present time) are reported in Table 1A. Median follow-up was 9 months (range 0-34). The two groups (HR and LR) had similar age, gender, and MIPI, but differed for LDH, and SUVmax at diagnosis, both being significantly more elevated in the HR group. The VR-BAC trial represents the first prospective study that stratified patients with MCL to different frontline treatments according to centralized on-time evaluation of the risk profile. We have shown that almost 40% of elderly patients with MCL in need of treatment have HR features. Data on tolerance, and tumor response will be presented at the meeting. Figure 1 View large Download slide Figure 1 View large Download slide  Close modal Disclosures Tisi:  GILEAD: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; BWS: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees. Zilioli:  Roche, Italfarmaco: Consultancy, Honoraria; MSD, Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations; Takeda: Other: travel expenses, accommodation; Gentili, Takeda, Gilead, Servier: Consultancy, Speakers Bureau. Corradini:  AbbVie, ADC Theraputics, Amgen, Celgene, Daiichi Sankyo, Gilead/Kite, GSK, Incyte, Janssen, KyowaKirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda: Honoraria; BMS: Other: Travel and accommodation; Novartis; Gilead; Celgene: Consultancy, Other: Travel and accommodations; Amgen; Takeda; AbbVie: Consultancy, Honoraria, Other: Travel and accommodations; KiowaKirin; Incyte; Daiichi Sankyo; Janssen; F. Hoffman-La Roche; Kite; Servier: Consultancy; Sanofi: Consultancy, Honoraria; Incyte: Consultancy; AbbVie, ADC Theraputics, Amgen, Celgene, Daiichi Sankyo, Gilead/Kite, GSK, Incyte, Janssen, KyowaKirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda: Consultancy; Novartis, Janssen, Celgene, BMS, Takeda, Gilead/Kite, Amgen, AbbVie: Other: travel and accomodations. Musuraca:  janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Puccini:  Takeda: Membership on an entity's Board of Directors or advisory committees. Cavallo:  Servier: Speakers Bureau; ROCHE: Membership on an entity's Board of Directors or advisory committees; Gilead: Speakers Bureau. Merli:  EUSA Pharma: Other: Travel, Accomodations, Expenses; Roche: Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accomodations, Expenses; Takeda: Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accomodations, Expenses; MSD: Membership on an entity's Board of Directors or advisory committees; Gilead Science: Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accomodations, Expenses; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accomodations, Expenses; Celgene: Other: Travel, Accomodations, Expenses. Ferreri:  PletixaPharm: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Research Funding; Beigene: Research Funding; Hutchison Medipharma: Research Funding; ADC Therapeutics: Research Funding; Adienne: Membership on an entity's Board of Directors or advisory committees; Genmab: Research Funding; Amgen: Research Funding; x Incyte: Membership on an entity's Board of Directors or advisory committees; Ospedale San Raffaele srl: Patents & Royalties; Pfizer: Research Funding. Santoro:  AstraZeneca: Speakers Bureau; AbbVie: Speakers Bureau; Amgen: Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Speakers Bureau; Sandoz: Speakers Bureau; Eli-Lilly: Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Eisai: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Speakers Bureau; Servier: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Speakers Bureau; Sanofi: Consultancy; Arqule: Consultancy, Speakers Bureau; Novartis: Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Zinzani:  KYOWA KIRIN: Other, Speakers Bureau; SERVIER: Other: Advisory board, Speakers Bureau; SANDOZ: Other: Advisory board; TG Therapeutics: Other: Advisory board, Speakers Bureau; ROCHE: Other, Speakers Bureau; BMS: Other: Advisory board, Speakers Bureau; TAKEDA: Other: Advisory board, Speakers Bureau; MSD: Consultancy, Other: Advisory board, Speakers Bureau; NOVARTIS: Consultancy, Other, Speakers Bureau; EUSAPHARMA: Consultancy, Other, Speakers Bureau; Beigene: Other, Speakers Bureau; ADC Therap.: Other; Incyte: Other, Speakers Bureau; JANSSEN-CILAG: Other: Advisory board, Speakers Bureau; GILEAD: Other: Advisory board, Speakers Bureau; CELLTRION: Other: Advisory board, Speakers Bureau; VERASTEM: Consultancy, Other: Advisory board, Speakers Bureau. OffLabel Disclosure: Venetoclax is off-label in Italy in mantle cell lymphoma",
    "author_names": [
        "Carlo Visco",
        "Valentina Tabanelli",
        "Claudia Peracchio",
        "Andrea Evangelista",
        "Maria Chiara Tisi",
        "Anna Merli",
        "Costanza Fraenza",
        "Stefano Fiori",
        "Alessandro Re",
        "Claudia Castellino",
        "Vittorio Ruggero Zilioli",
        "Francesco Piazza",
        "Paolo Corradini",
        "Stefan Hohaus",
        "Gerardo Musuraca",
        "Valeria Ferla",
        "Benedetta Puccini",
        "Federica Cavallo",
        "Filippo Ballerini",
        "Roberta Sciarra",
        "Alice Di Rocco",
        "Annalisa Arcari",
        "Carola Boccomini",
        "Francesco Merli",
        "Guido Gini",
        "Monica Tani",
        "Riccardo Bruna",
        "Vincenzo Pavone",
        "Andr\u00e9s J M Ferreri",
        "Armando Santoro",
        "Caterina Patti",
        "Giacomo Loseto",
        "Marco Ladetto",
        "Michele Merli",
        "Michele Spina",
        "Pier Luigi Zinzani",
        "Pietro Maria Stefani",
        "Sara Veronica Usai",
        "Caterina Stelitano",
        "Stefano Volpetti",
        "Stefano A Pileri",
        "Monica Balzarotti"
    ],
    "author_dict_list": [
        {
            "author_name": "Carlo Visco",
            "author_affiliations": [
                "Department of Medicine, Section of Hematology, University of Verona, Verona, ITA"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Valentina Tabanelli",
            "author_affiliations": [
                "Hematopathology Division, IEO Istituto Europeo di Oncologia IRCCS, Milano, Italy"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Claudia Peracchio",
            "author_affiliations": [
                "FIL, Fondazione Italiana Linfomi, Alessandria, Italy"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrea Evangelista",
            "author_affiliations": [
                "Citt\u00e0 Della Salute E Della Scienza, Torino, ITA"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Chiara Tisi",
            "author_affiliations": [
                "Department of Cell Therapy and Haematology, San Bortolo Hospital, Vicenza, Italy"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anna Merli",
            "author_affiliations": [
                "Ospedale degli Infermi, Rimini, ITA"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Costanza Fraenza",
            "author_affiliations": [
                "Department of Medicine, Section of Hematology, University of Verona, Verona, Italy"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Stefano Fiori",
            "author_affiliations": [
                "Hematopathology Division, IEO Istituto Europeo di Oncologia IRCCS, Milano, Italy"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alessandro Re",
            "author_affiliations": [
                "Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Claudia Castellino",
            "author_affiliations": [
                "Hematology Division, Santa Croce and Carle Hospital, Cuneo, Italy"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Vittorio Ruggero Zilioli",
            "author_affiliations": [
                "Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Piazza",
            "author_affiliations": [
                "Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padua, Italy"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paolo Corradini",
            "author_affiliations": [
                "Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Stefan Hohaus",
            "author_affiliations": [
                "University Policlinico Gemelli Foundation, IRCCS, Catholic University of the Sacred Heart, Roma, Italy"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gerardo Musuraca",
            "author_affiliations": [
                "Division of Hematology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\", Meldola, Italy"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Valeria Ferla",
            "author_affiliations": [
                "FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, MILANO, ITA"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Benedetta Puccini",
            "author_affiliations": [
                "Lymphoma Unit, Hematology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Federica Cavallo",
            "author_affiliations": [
                "Department of Molecular Biotechnologies and Health Sciences, Division of Hematology, University of Torino, Torino, Italy"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Filippo Ballerini",
            "author_affiliations": [
                "IRCCS Ospedale Policlinico San Martino, Clinic of Hematology, Department of Internal Medicine (DiMI), Genova, Italy"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Roberta Sciarra",
            "author_affiliations": [
                "Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alice Di Rocco",
            "author_affiliations": [
                "Department of Translational and Precision Medicine, Policlinico Umberto I, Roma, Italy"
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Annalisa Arcari",
            "author_affiliations": [
                "Hematology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy"
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carola Boccomini",
            "author_affiliations": [
                "Division of Haematology, Citt\u00e0 della Salute e della Scienza, Turin, Italy"
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Merli",
            "author_affiliations": [
                "Clinics and Public Health, Arcispedale S.Maria Nuova, University of Modena e Reggio Emilia, Hematology Division, Department of Diagnostic Medicine, Reggio Emilia, Italy"
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Guido Gini",
            "author_affiliations": [
                "Hematology, Department of Clinical and Molecular Sciences, Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy"
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Monica Tani",
            "author_affiliations": [
                "Hematology Unit, Ospedale Santa Maria delle Croci, Ravenna, Italy"
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Riccardo Bruna",
            "author_affiliations": [
                "Division of Hematology, Ospedale Maggiore Della Carit\u00e0, Novara, Italy"
            ],
            "author_rank": 27,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Vincenzo Pavone",
            "author_affiliations": [
                "Hematology, \"Card. G. Panico\" Hospital, Tricase, Italy"
            ],
            "author_rank": 28,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andr\u00e9s J M Ferreri",
            "author_affiliations": [
                "Onco-Hematology Department, Fondazione Centro San Raffaele, Milan, Italy"
            ],
            "author_rank": 29,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Armando Santoro",
            "author_affiliations": [
                "Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas University, Milan, Italy"
            ],
            "author_rank": 30,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Caterina Patti",
            "author_affiliations": [
                "Division of Onco-Hematology, Azienda Villa Sofia Cervello, Palermo, Italy"
            ],
            "author_rank": 31,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giacomo Loseto",
            "author_affiliations": [
                "Division of Hematology, IRCCS Ospedale Oncologico Giovanni Paolo II, Bari, Italy"
            ],
            "author_rank": 32,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marco Ladetto",
            "author_affiliations": [
                "Dipartimento di Medicina Traslazionale, Universit\u00e0 del Piemonte Orientale, Alessandria, Italy"
            ],
            "author_rank": 33,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michele Merli",
            "author_affiliations": [
                "Hematology, University Hospital \"Ospedale di Circolo e Fondazione Macchi\" - ASST Sette Laghi, University of Insubria, Varese, Italy"
            ],
            "author_rank": 34,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michele Spina",
            "author_affiliations": [
                "Division of Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy"
            ],
            "author_rank": 35,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pier Luigi Zinzani",
            "author_affiliations": [
                "University of Bologna, Istituto Di Ematologia, Bologna, Italy"
            ],
            "author_rank": 36,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pietro Maria Stefani",
            "author_affiliations": [
                "Ca' Foncello Hospital, Haematology Unit,, Treviso, Italy"
            ],
            "author_rank": 37,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sara Veronica Usai",
            "author_affiliations": [
                "Ospedale Businco, S.C Ematologia e CTMO, Cagliari, Italy"
            ],
            "author_rank": 38,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Caterina Stelitano",
            "author_affiliations": [
                "Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, ITA"
            ],
            "author_rank": 39,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Stefano Volpetti",
            "author_affiliations": [
                "Clinic of Hematology, Presidio Ospedaliero Universitario \"Santa Maria della Misericordia\" di Udine, ASUFC, Udine, Italy"
            ],
            "author_rank": 40,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Stefano A Pileri",
            "author_affiliations": [
                "Hematopathology Division, IEO Istituto Europeo di Oncologia IRCCS, Milano, Italy"
            ],
            "author_rank": 41,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Monica Balzarotti",
            "author_affiliations": [
                "Unit of Hematology, Humanitas Clinical and Research Center, Rozzano, Italy"
            ],
            "author_rank": 42,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-22T18:45:29",
    "is_scraped": "1"
}